AXA IM Global Health

AXA IM Alts’ Global Health Strategy is an actively managed private equity impact fund launched in April 2022. It invests globally in innovative healthcare companies developing medical devices, biopharmaceuticals, vaccines, and diagnostics that address major global health challenges. The strategy prioritizes late-stage clinical or early commercial-stage companies with products that can be delivered at accessible price points to high-volume markets—including low-, middle-, and high-income countries—aiming for both financial returns and measurable social impact aligned with UN Sustainable Development Goals. Notable investments include Biolinq (glucose sensors), Maternal Newborn Health Innovations (maternal/newborn mortality), CXL Ophthalmics (keratoconus treatment), Axena Health (women’s health devices), among others.